iSpecimen (ISPC) Stock Price, News & Analysis

Company Overview

iSpecimen, Inc. (NASDAQ:ISPC) operates an online life sciences marketplace designed to connect researchers with human biological specimens and associated clinical data. The company’s platform streamlines the sourcing of biospecimens—such as plasma, serum, fresh and frozen tissue, saliva, urine and peripheral blood mononuclear cells (PBMCs)—by matching demand from pharmaceutical, biotechnology, diagnostic and academic organizations with supply from a wide network of clinical sites and biobanks.

Through its on-demand procurement model, iSpecimen provides customized specimen collection and fulfillment services that help accelerate research timelines and improve data quality. Clients can specify criteria such as disease state, treatment history, demographics and sample processing requirements, while the company manages regulatory compliance, informed consent documentation and quality assurances in accordance with HIPAA, FDA and international guidelines.

Founded in 2015 and headquartered in Boston, Massachusetts, iSpecimen has gradually expanded its footprint to include partnerships with specimen providers across North America and select global markets. The company leverages its proprietary technology and centralized logistics to reduce lead times and deliver specimens and data under controlled chain-of-custody conditions. Over time, iSpecimen has supported thousands of research studies spanning oncology, neurology, immunology, cardiovascular disease and infectious disease.

Under the leadership of founder and CEO Eddie Clarke, iSpecimen continues to evolve its platform by adding new specimen types, enhancing data annotation tools and forging collaborations with contract research organizations and diagnostic developers. The company’s marketplace model aims to address critical bottlenecks in translational and clinical research by making high-quality human biospecimens more accessible to investigators worldwide.

Key Stats

• Today's Range: $2.72 to $2.92
• 50-Day Range: $2.68 to $6.49
• 52-Week Range: $2.54 to $127.20
• Volume: 108,522 shs
• Average Volume: 235,423 shs
• Market Capitalization: $3.96 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

iSpecimen Stock Analysis - MarketRank™

iSpecimen scored higher than 7% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

iSpecimen has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

iSpecimen has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of iSpecimen is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of iSpecimen is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

iSpecimen has a P/B Ratio of 0.19. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

19.10% of the float of iSpecimen has been sold short.

Short Interest Ratio / Days to Cover

iSpecimen has a short interest ratio ("days to cover") of 0.62, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in iSpecimen has recently increased by 113.63%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

iSpecimen does not currently pay a dividend.

Dividend Growth

iSpecimen does not have a long track record of dividend growth.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.44

News Sentiment

iSpecimen has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.81 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for iSpecimen this week, compared to 2 articles on an average week.

Search Interest

Only 4 people have searched for ISPC on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

MarketBeat Follows

2 people have added iSpecimen to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.6 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, iSpecimen insiders have not sold or bought any company stock.

Percentage Held by Insiders

12.20% of the stock of iSpecimen is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

13.62% of the stock of iSpecimen is held by institutions.

Company Calendar

• Last Earnings: 5/15/2026
• Today: 6/13/2026
• Next Earnings (Estimated): 8/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Business Services
• Current Symbol: NASDAQ:ISPC
• CIK: 1558569
• Web: ispecimen.com
• Phone: 781-301-6700
• Fax: N/A
• Employees: 60
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($72.26)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$10.49 million
• Net Margins: -1,080.16%
• Pretax Margin: -1,080.25%
• Return on Equity: -584.65%
• Return on Assets: -142.48%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.62
• Quick Ratio: 0.62

Sales & Book Value

• Annual Sales: $1.93 million
• Price / Sales: 2.05
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $14.57 per share
• Price / Book: 0.19

Miscellaneous

• Outstanding Shares: 1,440,000
• Free Float: 1,262,000
• Market Cap: $3.96 million
• Optionable: Not Optionable
• Beta: 1.62